Oral nonsteroidal anti-inflammatory drugs for neuropathic pain

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Moore, R Andrew ^a   Chi, Ching Chi ^b,c   Wiffen, Philip J ^a   Derry, Sheena ^a   Rice, Andrew S C ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; CELECOXIB; GW 406381; PREGABALIN; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

CHRONIC PAIN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; HUMAN; LOW BACK PAIN; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; ADULT; BACK PAIN; META ANALYSIS; NEURALGIA; NEURALGIA, POSTHERPETIC; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACK PAIN; CELECOXIB; HUMANS; NEURALGIA; NEURALGIA, POSTHERPETIC; PREGABALIN; PYRAZOLES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84979859257     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010902.pub2     Document Type: Review

References (76)

1. Romanò CL, Romanò D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. Journal of Orthopaedics and Traumatology 2009;10(4):185-91. [DOI: 10.1007/s10195-009-0077-z]3140627
2. Shackelford S, Rauck R, Quessy S, Blum D, Hodge R, Philipson R. A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia. Journal of Pain 2009;10(6):654-60. [DOI: 10.1016/j.jpain.2009.01.328]3140629
3. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Archives of Internal Medicine 1987;147(8):1442-4. [DOI: 10.1001/archinte.1987.00370080078016]3140631
4. Dellemijn PL, Verbiest HB, van Vliet JJ, Roos PJ, Vecht CJ. Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine. European Journal of Cancer 1994;30A(9):1244-50. [PUBMED: 7999406]3140633
5. Jaffé G. A double-blind, between patient comparison of alclofenac ("Prinalgin")and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion 1974;2(7):424-9. [PUBMED: 4281380]3140635
6. Patarica-Huber E, Boskov N, Pjevic M. Multimodal approach to therapy-related neuropathic pain in breast cancer. Journal of B.U.ON. 2011;16(1):40-5. [PUBMED: 21674848]3140637
7. Pop-Busui R. Pilot study to determine effects of salsalate in type 1 diabetes and painful peripheral neuropathy (SALP). clinicaltrials.gov/ct2/show/NCT01480297 (accessed 5 June 2015) 2015. 3140639
8. Solak O, Metin M, Esme H, Solak O, Yaman M, Pekcolaklar A, et al. Effectiveness of gabapentin in the treatment of chronic post-thoracotomy pain. European Journal of Cardio-thoracic Surgery 2007;32(1):9-12. [DOI: 10.1016/j.ejcts.2007.03.022]3140641
9. Videman T, Osterman K. Double-blind parallel study of piroxicam versus indomethacin in the treatment of low back pain. Annals of Clinical Research 1984;16(3):156-60. [PUBMED: 6236738]3140643
10. Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine 1993;18(11):1433-8. [PUBMED: 8235813]3140645
11. Yu C, Chen Y, Mu Y, Chen X, Ding X, Ya W. Effect of oxycodone and acetaminophen on postherpetic neuralgia. Chinese Journal of New Drugs 2008;17(23):2061-2. 3140647
12. Maier C. Efficacy of etoricoxib on peripheral hyperalgesia. www.clinicaltrials.gov/ct2/show/NCT01088256 (accessed 5 June 2015) 2012. 3140649
13. Ratcliffe S. Evaluation of the efficacy, tolerability and safety of etoricoxib (Arcoxia) in patients with neuropathic pain. www.clinicaltrials.gov/ct2/show/NCT01264237 (accessed 5 June 2015) 2011. 3140651
14. Pfizer. Efficacy and safety study of celecoxib and pregabalin compared with celecoxib monotherapy, in patients with chronic low back pain having a neuropathic component. www.clinicaltrials.gov/ct2/show/NCT01838044 (accessed 5 June 2015) 2015. 3140653
15. Baron R, Wasner G, Binder A. Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology 2012;11(1):19-21. [DOI: 10.1016/S1474-4422(11)70281-2]
16. Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, et al. Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. Medscape Journal of Medicine 2008;10(11):259.
17. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7. [DOI: 10.1016/j.pain.2007.08.013]
18. Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain. Lancet Neurology 2012;11(7):629-42. [DOI: 10.1016/S1474-4422(12)70134-5]
19. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. http://papas.cochrane.org/papas-documents (accessed 5 June 2015) 2012.
20. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 2014;155(11):2263-73. [DOI: 10.1016/j.pain.2014.08.014]
21. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111]
22. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3]
23. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010958.pub2]
24. Di Franco M, Iannuccelli C, Atzeni F, Cazzola M, Salaffi F, Valesini G, et al. Pharmacological treatment of fibromyalgia. Clinical and Experimental Rheumatology 2010;28(6 Suppl 63):S110-6. [PUBMED: 21176430]
25. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
26. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018391.pdf (accessed 25 Spetember 2015).
27. FDA Public Health Advisory: Safety of Vioxx. fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106274.htm (accessed 25 September 2015).
28. Finnerup NB, Scholz J, Attal N, Baron R, Haanpää M, Hansson P, et al. Neuropathic pain needs systematic classification. European Journal of Pain 2013;17(7):953-6. [DOI: 10.1002/j.1532-2149.2012.00282.x]
29. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology 2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]
30. Grosser T, Smyth E. Chapter 34. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. In: Brunton LL, Chabner BA, Knollmann BC editor(s). Goodman & Gilman's The Pharmacological Basis of Therapeutics. Available at accessmedicine.mhmedical.com/book.aspx?bookid=374 (accessed 5 Jun 2015). 12th Edition. New York: McGraw-Hill, 2011. [ISBN: 978-0-07-162442-8]
31. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132-6. [DOI: 10.1111/j.1399-6576.2007.01486.x]
32. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26]
33. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013;14:28. [DOI: 10.1186/1471-2296-14-28]
34. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience 2007;144(4):1495-508. [DOI: 10.1016/j.neuroscience.2006.11.029]
35. Helfert SM, Reimer M, Höper J, Baron R. Individualized pharmacological treatment of neuropathic pain. Clinical Pharmacology and Therapeutics 2015;97(2):135-42. [DOI: 10.1002/cpt.19]
36. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org (accessed 5 June 2015).
37. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: doi.org/10.1016/0197-2456(95)00134-4]
38. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204-5. [DOI: 10.1016/j.pain.2011.06.017]
39. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10(5-6):276-81. [PUBMED: 1798430]
40. Kawakami M, Matsumoto T, Hashizume H, Kuribayashi K, Tamaki T. Epidural injection of cyclooxygenase-2 inhibitor attenuates pain-related behavior following application of nucleus pulposus to the nerve root in the rat. Journal of Orthopaedic Research 2002;20(2):376-81. [DOI: 10.1016/S0736-0266(01)00114-0]
41. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1-3):122-7. [DOI: 10.1016/j.pain.2009.08.023]
42. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33.
43. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120(3):594-606. [DOI: 10.1053/gast.2001.21907]
44. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009;151(4):W65-94. [DOI: 10.7326/0003-4819-151-4-200908180-00136]
45. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
46. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. 1st Edition. Oxford University Press, 1998. [ISBN: 978-0192630483]
47. McQuay HJ, Smith LA, Moore RA. Chronic Pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd series. Oxford: Radcliffe Publishing, 2007. [ISBN: 978-1-84619-063-6]
48. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
49. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
50. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
51. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: [10.1136/ard.2009.107805]]
52. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]
53. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.013]
54. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
55. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]
56. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030]
57. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
58. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]
59. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
60. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
61. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014; Vol. 14, issue 1:79-94. [DOI: 10.1111/papr.12050]
62. National Institute for Health and Care Excellence (NICE). Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 5 June 2015).
63. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]
64. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56(2):127-38. [DOI: 10.1016/0304-3959(94)90086-8]
65. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
66. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD004844.pub3]
67. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
68. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia - responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150]
69. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
70. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281-9. [DOI: 10.1016/j.jpain.2005.11.008]
71. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5. [DOI: 10.1212/01.wnl.0000282763.29778.59]
72. Varner J, Lomax M, Blum D, Quessy S. A randomized, controlled, dose-ranging study investigating single doses of GW406381, naproxen sodium, or placebo in patients with acute pain after third molar tooth extraction. Clinical Journal of Pain 2009;25(7):577-83. [DOI: 10.1097/AJP.0b013e3181a085fa]
73. Vo T, Rice ASC, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: How do we explain continued widespread use?. Pain 2009;143(3):169-71. [DOI: 10.1016/j.pain.2009.03.013]
74. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638-52. [DOI: 10.1016/j.neuron.2012.02.008]
75. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]
76. Wentz AL, Jimenez TB, Dixon RM, Aurora SK, Gold M, CXA20008 Study Investigators. A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine. European Journal of Neurology 2008;15(4):420-7. [DOI: 10.1111/j.1468-1331.2008.02093.x]